cyclosporin-c and Kidney-Diseases

cyclosporin-c has been researched along with Kidney-Diseases* in 1 studies

Other Studies

1 other study(ies) available for cyclosporin-c and Kidney-Diseases

ArticleYear
The role of candidate genetic polymorphisms in the interaction between voriconazole and cyclosporine in patients undergoing allogeneic hematopoietic cell transplantation: An explorative study.
    Current research in translational medicine, 2020, Volume: 68, Issue:2

    To evaluate polymorphisms in genes of drug metabolizing enzymes and transporters involved in cyclosporine and/or voriconazole disposition among patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT).. DNA from forty patients was genotyped using the DMETPlus array. The average ratio of cyclosporine concentration/dose (C/D in (ng/mL)/(mg/kg)) per participant's weight was computed using available trough levels and daily doses.. The C/D cyclosporine ratio was significantly higher when it was administered with voriconazole as compared to when it was administered alone: median: 116.75 vs. 25.40 (ng/mL)/(mg/kg) with and without voriconazole respectively, (P < 0.001). There was also a significant association between the C/D cyclosporine ratio combined with voriconazole and the ABCB1 2677 G > T > A (rs2032582) genetic polymorphism (P = 0.05). In parallel, ABCB1 variant allele carriers had higher creatinine in combination therapy with a median creatinine (mg/dL) of 0.74 vs. 0.56 for variant allele carriers vs. reference; P = 0.003. Interestingly, CYP2C9, CYP2C19, and CYP3A5 extensive metabolizers tended to be associated with lower cyclosporine C/D ratio when combined with voriconazole, but the results were not statistically significant.. To the best of our knowledge, this is the first pharmacogenetic study on the interaction between voriconazole and cyclosporine in patients undergoing allo-HCT. Results suggest that the ABCB1 2677 G > T > A genetic polymorphism plays a role in this interaction with cyclosporine related nephrotoxicity. Pre-emptive genotyping for this genetic variant may be warranted for cyclosporine dose optimization. Larger studies are needed to potentially show significant associations with more candidate genes such as CYP3A4/5, CYP2C9, and CYP2C19, among others.

    Topics: Adult; Aged; Allografts; Antifungal Agents; ATP Binding Cassette Transporter, Subfamily B; Biotransformation; Carrier Proteins; Cyclosporine; Cyclosporins; Cytochromes; Dose-Response Relationship, Drug; Drug Interactions; Female; Genetic Association Studies; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kidney Diseases; Male; Middle Aged; Pharmacogenomic Testing; Pilot Projects; Transplantation Conditioning; Voriconazole; Young Adult

2020